Rhythm Pharmaceuticals Presents New Data at ESPE 2023
BOSTON, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the...
Brain
Brain Canada’s flagship program awards $2.8 million for brain research
Brain Canada’s Future Leaders in Canadian Brain Research program to support 28 early-career researchers this year The 2022 Future Leaders...
Cognetivity Neurosciences Partners with No Fear Counselling to Pioneer Brain Health Assessment Through Groundbreaking AI Technology
New Approach to Measuring Impact of Counselling to Deliver Next Generation Care to Mental Health Sufferers in North AmericaVancouver, British...
Relievant Medsystems Introduces Intracept Simulator System Powered by Medability for Improved and Expanded Physician Training Opportunities
Advanced technology enhances Intracept Procedure training for the treatment of vertebrogenic painCHICAGO, Sept. 21, 2023 (GLOBE NEWSWIRE) -- IPSIS Annual...
Biodexa to Present Recruitment and Treatment Update in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma at 2023 Annual European Association of Neuro-Oncology Meeting (EANO)
Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa to Present Recruitment and Treatment Update in Phase 1 Study of MTX-110 (MAGIC-G1...
Replay announces partnership between product company Syena and JURA Bio to advance T cell receptor NK therapies in cancer
Replay announces partnership between product company Syena and JURA Bio to advance T cell receptor NK therapies in cancer Collaboration...
NeurAxis Reports Second Quarter 2023 Financial Results
CARMEL, Ind., Sept. 21, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS) (“NeurAxis” or the “Company”), a medical technology company...
Helius to Bring its Innovative PoNS Therapy for Improvement of Gait in People with MS, to the 2023 Academy of Neurologic Physical Therapy Conference
Company’s First-Ever ANPT Booth Sponsorship Enables Specialists to Learn More about this Breakthrough Technology on Eve of National Physical Therapy...
Halberd and Athena GTX Collaborate on Advanced Traumatic Brain Injury (TBI) Monitoring and Applications for Government Contracts
JACKSON CENTER, PA / ACCESSWIRE / September 20, 2023 / Halberd Corporation (OTC PINK:HALB) and Athena GTX, Inc, of Johnston,...
Inhibikase Therapeutics Issues a Letter to Shareholders and Comments on Recent Trading Activity
BOSTON and ATLANTA, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical...
AlzeCure presents positive phase II clinical data with ACD440 against neuropathic pain at EFIC 2023 Conference
STOCKHOLM, SE / ACCESSWIRE / September 20, 2023 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR),...
Red Light Holland: Mistercap’s Launches Organic Grow-Your-Own Mushroom Kits for Sale at www.Mistercap.com
Toronto, Ontario--(Newsfile Corp. - September 19, 2023) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light...
CANAQUEST Announces Award of European Cannabinoid Patent
EU Patent #19846183.2 - A NOVEL BOTANICAL AND TETRAHYDROCANNABINOL ("THC") FORMULATION FOR THE REDUCTION OF CANNABIS-INDUCED NEGATIVE NEUROPSYCHIATRIC SIDE-EFFECTSWe believe...
Cerevance Doses First Subject in Phase 1 Clinical Study of CVN293, a Selective Inhibitor of KCNK13 Designed to Selectively Modulate Neuroinflammation, for the Treatment of ALS and Alzheimer’s Disease
BOSTON, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on advancing novel,...
Rhythm Pharmaceuticals Receives Orphan Drug Designation from European Medicines Agency for Setmelanotide for Treatment of Acquired Hypothalamic Obesity
BOSTON, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the...
FSD Pharma announces Interim Results from First-in-Human Clinical Trial of Lucid-MS (Lucid-21-302) for Multiple Sclerosis; The Report Shows Compound to be Safe and Well Tolerated
TORONTO, ON / ACCESSWIRE / September 18, 2023 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical...
Aruna Bio Announces Presentation on the Mechanism of its Neural Exosome Platform and Lead Program, AB126, at the BioProcess International Conference & Exhibition
– AB126, an unmodified exosome derived from neural stem cells, shows native therapeutic activity with anti-inflammatory and neuroprotective properties through modulation...
Safety Shot to Develop Detox Product for Alcohol Poising, Plans to File IND with U.S. FDA
Concentrated form of Safety Shot may be effective as a rapid treatment for alcohol poising which causes 2,200 deaths each...
AlzeCure Gets an Abstract on Phase II Clinical Data with ACD440 for Neuropathic Pain Accepted at Pain Conference
STOCKHOLM, SWEDEN / ACCESSWIRE / September 18, 2023 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), )...
CD34 NU-Signals and Alzheimer’s Disease Human Trials Presentation With Tzu Chi Hospital and Beauty-Stem Biomedical, Subsidiary of Power-Stem Biomedical Group
Unveiling the Potential Breakthrough - Activating Stem Cells to Delay and Reduce Dementia and Depression RiskLOS ANGELES, CA / ACCESSWIRE...